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INVESTIGATING OF INTERACTIONS BETWEEN STATIN-BASED 
CHOLESTEROL LOWERING DRUGS  WITH P-GLYCOPROTEIN 
MEMBRANE PROTEIN BY MOLECULAR MODELING 
SUMMARY 
P-glycoprotein (Pgp) is a multidrug resistance protein whose function is to expel the 
toxic compounds out of the cell and in this way protect the cell from the harmful 
effect of these compounds. Pgp plays a critical role during medication since it can 
export different types of drugs ranging from cancer therapeutics to cardiovascular 
disease drugs. In order to increase the effectiveness of these drugs, there is a need to 
block Pgp or design drugs which can bypass Pgp during medication. To be able to do 
that, it is first necessary to understand mechanism of Pgp. 
The aim of this study is to understand the mechanism of Pgp by using molecular 
dynamic simulation. To do this, ALLM (N-acetyl-lue-leu-methinonal), AFMRF (N-
acetyl-phe-met-arg-phe-al) linear peptides known as Pgp substrates and atorvastatin, 
a cholesterol lowering drug, was used as model compounds. First, the integration of 
the Pgp into a lipid bilayer was done and its stability was checked. Then to supply 
the required energy for transportation, two MgATP were docked into the nucleotide 
binding pocket of Pgp. For each simulation, different substrates were docked into 
this system and simulated for 10 ns.   
As a result of the simulations, no interaction could be detected between the linear 
peptides and Pgp. The reason of this situation could be the insufficient number of 
peptide per transport cycle used during simulations. Pgp can export more than one 
molecule per transport cycle and need to fill its pocket with enough molecules to 
function.  Lactone form of atorvastatin, on the other hand, was found to interact with 
Pgp as expected and led to an asymmetrical closure of nucleotide binding domains 
during 10 ns simulation.  
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BİR MEMBRAN PROTEİNİ OLAN P-GLİKOPROTEİNİN STATİN BAZLI 
KOLESTEROL DÜŞÜRÜCÜ İLAÇLARLA ETKİLEŞİMİNİN MOLEKÜLER 
MODELLEME YOLUYLA İNCELENMESİ 
ÖZET 
P-glikoprotein (Pgp), bir çoklu-ilaç direnç proteini olup fonksiyonu toksik maddeleri 
hücreden uzaklaştırma yolu ile hücreyi bu maddelerin zararlı etkilerin korumaktır.  
Pgp, kanser terapiden kalp damar hastalıklarına kadar çeşitli tipte ilaçı 
uzaklaştırabildiği için tedavi sürecinde kritik rol oynar.  Bu ilaçların etkisini 
artırabilmek için Pgp’nin çalışmasını durduracak yada Pgp’ye uğramadan hücreye 
ulaşabilecek  ilaçların tasarlanmasına ihtiyaç vardır. Bunu başarabilmek için ilk 
olarak Pgp’nin mekanizmasını anlamak gerekmektedir.  
Bu çalışmanın amacı moleküler dinamik simülasyon kullanarak Pgp’nin 
mekanizmasını anlamaktır. Bunun için Pgp substratı olduğu bilinen ALLM (N-asetil-
leu-leu-met-al), AFMRF (N-asetil-phe-met-arg-phe-al) doğrusal peptidleri ve 
kolesterol düşürücü atorvastatin’nin lakton formu örnek molekül olarak kullanıldı. 
İlk olarak Pgp’nin lipid zar içine yerleştirilmesi gerçekeştirildi ve stabilitesi gözden 
geçirildi.  Arkasından Pgp nin taşıma için gerekli enerjiyi tedariğine yönelik 
proteinin ilgili nükleotid bağlanma bölgelerine iki adet MgATP molekülü 
yerleştirildi. Her bir simülasyon için oluşturulan bu yapıya farklı substratlar 
yerleştirildi ve 10 ns boyunca simüle edildi.    
Çalışma neticesinde doğrusal peptid zincirlerinin pek Pgp ile etkileşmediği gözlendi. 
Bunun sebebi peptid büyüklüklerinin yetersiz kalması olabilir. Çünkü Pgp aynı anda 
birden fazla ilaçı taşıyabilme kapasitesine sahip bir proteindir. Bu peptidler için de 
birden fazlası taşıma için gerekli olabilir. Ancak diğer taraftan atorvastatin lakton 
formu Pgp ile beklenen şekilde etkileşime girdi ve 10 ns simülasyon boyunca  
nükleotid bağlanma domainlerinde asimetrik bir kapanmaya neden oldu. 
  
xviii 
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1.  INTRODUCTION 
1.1 P-glycoprotein 
1.1.1 The ABC transporters 
P-glycoprotein (Pgp) is a 170 kDa member of the ATP-Binding cassette (ABC) 
transporters superfamily that was first identified in drug-resistant Chinese hamster 
ovary cells by its ability to reduce the rate of drug uptake. Cell lines that were 
initially selected for resistance to one cytotoxic drug were later shown to display 
cross-resistance to other structurally unrelated cytotoxic compounds [1-3]. In nearly 
all cases, the drug-resistant cell lines showed over-expression of a 170 kDa 
glycosylated plasma membrane protein when compared to the drug-sensitive parent 
cell lines [4,5]. The protein was termed P-glycoprotein (Pgp) because it appeared to 
affect the permeability of the membrane to cytotoxic compounds [6]. 
In 1986, three groups reported the cloning and sequencing of the gene responsible for 
Pgp-mediated drug resistance from hamster [7], human [8] and mouse [9] cell lines. 
It is a product of the MDR1 (ABCB1) gene in humans and has two homologues in 
mice (abcbla and abcblb). It was subsequently shown that Pgp is an ATP-dependent 
drug pump that can transport a broad range of structurally unrelated compounds out 
of the cell [10].  
ATP-binding cassette transporters (ABC-transporter) are members of a protein 
superfamily that is one of the largest and most ancient families with representatives 
in all extant phyla from prokaryotes to humans [11]. ABC transporters are 
transmembrane proteins that utilize the energy of adenosine triphosphate (ATP) 
hydrolysis to carry out certain biological processes including translocation of various 
substrates across membranes [12,13] and non-transport-related processes such as 
translation of RNA and DNA repair [14]. They transport a wide variety of substrates 
across extra- and intracellular membranes, including metabolic products, lipids and 
sterols, and drugs. Proteins are classified as ABC transporters based on the sequence 
and organization of their ATP-binding cassette (ABC) domain(s). ABC transporters 
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are involved in tumour resistance, cystic fibrosis, bacterial multidrug resistance, and 
a range of other inherited human diseases. 
Cellular survival requires the generation and maintenance of electrical and chemical 
concentration gradients across the generally impermeable cell membrane. ATP-
binding cassette (ABC) transporters are key participants in this process, and typically 
use the favourable chemical energy of ATP hydrolysis to translocate molecules 
across membranes in a thermodynamically unfavourable direction. ABC transporters 
function as either importers, which bring nutrients and other molecules into cells, or 
as exporters, which pump toxins, drugs and lipids across membranes. 
Members of the ABC transporter family are present in organisms from all kingdoms 
of life; whereas exporters are found in both eukaryotes and prokaryotes, importers 
seem to be present exclusively in prokaryotic organisms. ABC transporters constitute 
the largest protein family in E. coli, including 80 distinct systems that represent 5% 
of the genome [18], whereas 50 ABC transporters are present in humans [19] and 
seventeen of these proteins are source of some diseases [20]. 
ABC transporters have a characteristic architecture that consists minimally of four 
domains Figure 1.1: two transmembrane domains (TMDs) that are embedded in the 
membrane bilayer, and two ABCs (or nucleotide-binding domains (NBDs)) that are 
located in the cytoplasm. At the sequence level, the superfamily of ABC transporters 
is identified by a characteristic set of highly conserved motifs that are present in the 
ABCs. By contrast, the sequences and architectures of the TMDs are variable, 
reflecting the chemical diversity of the translocated substrates. Beyond these four 
domains, additional elements can fuse to the TMDs and/or ABCs of ABC 
transporters and probably have regulatory functions [21]. For prokaryotic ABC 
transporters that function as importers, substrate translocation is also dependent on 
another protein component, a high-affinity binding protein that specifically 
associates with the ligand in the periplasm for delivery to the appropriate ABC 
transporter [22]. In ABC importers, the TMDs and NBDs are separate polypeptide 
chains. In bacterial exporters, by contrast, a TMD is fused to a NBD, generating a 
'halftransporter' that forms a homodimer or heterodimer to generate the functional 
unit. Many eukaryotic ABC exporters are expressed with all four domains in a single 
polypeptide chain [23]. 
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Figure 1.1 : Molecular architecture of ABC transporters. A) A cartoon of the 
modular organization of ATP-binding cassette (ABC) transporters, 
which are composed of two transmembrane domains (TMDs) and two 
ABC domains (or nucleotide-binding domains). The binding protein 
component that is required by importers is also shown. Two 
conformational states of the ABC transporter-outward facing and inward 
facing, with the substrate-binding site orientated towards the periplasmic 
(extracellular) and cytoplasmic (intracellular) regions, respectively - are 
depicted to show the alternating access mechanism of transport. B) The 
E. coli vitamin B12 importer BtuCDF[15] (PDB  2QI9). The core 
transporter consists of four subunits: the two TMD BtuC subunits (green 
and blue) and the two ABC BtuD subunits (yellow and magenta). This 
complex also contains one copy of BtuF, the periplasmic binding protein 
(pink). C) The mouse p-glycoprotein multidrug exporter [16] (PDB 
3G60). P-glycoprotein is a monomer and all four domain is combined 
into a single polypeptide chain. D) The Staphylococcus aureus Sav1866 
multidrug exporter [17] (PDB code 2HYD). Sav1866 consists of two 
subunits (green and blue), which contain a fused TMD and ABC 
domain. The nucleotides that are bound in this structure are shown by 
space-filling models. ICL, intracellular loop. 
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1.1.2 Tissue distribution 
Early studies of Pgp distribution in human [24] and rodent [25] tissues showed that 
the protein is expressed at low levels in most tissues but is found in much higher 
amounts at the apical surface of epithelial cells lining the colon, small intestine, 
pancreatic ductules, bile ductules and kidney proximal tubules, and the adrenal 
gland. Thus, epithelial cells with excretory roles generally express Pgp. The 
transporter is also located in the endothelial cells of the blood–brain barrier [26], the 
blood–testis barrier [27], and the blood–mammary tissue barrier [28], and has 
recently been found to play a role in the blood–inner ear barrier, where it is 
expressed in the capillary endothelial cells of the cochlea and vestibule [29]. Thus 
the role of Pgp in the blood–brain and blood–tissue barriers is likely to protect these 
organs from toxic compounds that gain entry into the circulatory system. Pgp is 
expressed at high levels at the luminal surface of secretory epithelial cells in the 
pregnant endometrium [30], as well as the placenta [31], where it may provide 
protection for the fetus [32]. The protein is also found on the surface of 
hematopoietic cells, where its function remains enigmatic. The ABCB4 protein is 
expressed at high levels on the bile canalicular membrane of hepatocytes, in 
accordance with its proposed role in transport of PC into the bile [33]. 
1.1.3 Physiological role 
The tissue localization of Pgp suggests that the protein plays a physiological role in 
the protection of susceptible organs such as the brain, testis, and inner ear from toxic 
xenobiotics, the secretion of metabolites and xenobiotics into bile, urine, and the 
lumen of the gastrointestinal tract, and possibly the transport of hormones from the 
adrenal gland and the uterine epithelium. These ideas have been strongly supported 
by studies on transgenic knockout mice lacking one or both of the genes encoding 
the drug-transporting Pgps Abcb1a and Abcb1b. Both single- and double-knockout 
mice are fertile, viable, and phenotypically indistinguishable from wild-type mice 
under normal conditions. So Pgp does not appear to fulfill any essential physiological 
functions. However, Pgp knockout mice showed radical changes in the way that they 
handled a challenge with many drugs [34]. mdr3 knockout mice displayed a 
disrupted blood–brain barrier and were 100-fold more sensitive to the pesticide 
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ivermectin, which was neurotoxic to the animals [35]. This Pgp isoform appears to 
play the major role in preventing accumulation of drugs in the brain [34,36]. The 
double-knockout mouse has proved useful in evaluating the effect of Pgp-mediated 
transport on drugs that are targeted to the central nervous system [37]. Certain dogs 
of the collie lineage [38] and several other dog breeds [39,40] have a naturally 
occurring lack of Pgp due to a frameshift mutation in the MDR1 gene and are also 
hypersensitive to ivermectin. To date, no human null alleles have been reported, 
despite widespread use of drugs that are Pgp substrates. 
Pgp in the intestinal epithelium plays an important role in the extrusion of many 
drugs from the blood into the intestinal lumen, and in preventing drugs in the 
intestinal lumen from entering the bloodstream. Pgp activity can therefore reduce the 
absorption and oral bioavailability of those drugs that are transport substrates. Due to 
the prevalence of Pgp in a variety of barrier tissues, and the physiological role that it 
plays in the bioavailability and pharmacokinetics of clinically administered drugs, 
the interaction of drugs with Pgp is an important factor that needs to be considered 
when designing a treatment regimen. 
1.1.4 Multidrug resistance 
The overexpression of Pgp is one of the main causes of cancer cells becoming 
simultaneously resistant to multiple chemotherapeutic drugs, resulting in a condition 
known as multidrug resistance (MDR) [41]. The development of MDR is a major 
obstacle to treating cancer, and Pgp is thought to contribute to chemotherapy drug 
resistance in 50% of human cancers [10]. Some tumours are inherently drug-
resistant, whereas others develop MDR over the course of treatment. Cancers of the 
colon, liver, pancreas and kidney tend to be intrinsically drug-resistant, whereas 
leukemias, myeloma, ovarian and breast cancers tend to develop MDR as a result of 
chemotherapeutic intervention. Cancers that acquire MDR due to overexpression of 
Pgp after chemotherapy show a greater response to Pgp inhibitors than cancers 
expressing elevated levels of Pgp at the time of diagnosis, likely because other 
mechanisms of resistance are present in the latter [42]. The ability of Pgp to confer 
drug resistance in vivo has been demonstrated with the retroviral transfer of MDR1 
into murine bone marrow cells, resulting in resistance to the cytotoxic drug taxol 
[43]. Using positron emission tomography and n C-labelled verapamil as a substrate, 
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cyclosporin A was shown to inhibit the human BBB Pgp [44]. This method is useful 
for monitoring the in vivo activity of Pgp. 
Since Pgp causes in vivo drug resistance, inhibition of Pgp-mediated drug efflux has 
been proposed as one way to increase the uptake of chemotherapy drugs into MDR 
tumour cells. Pgp modulators, which are MDR reversal agents, block the drug efflux 
ability of Pgp by interacting at either the substrate binding pocket [45], or one of 
several proposed allosteric binding sites [46]. Pgp modulators alone are not toxic to 
MDR cells, but a combination of modulator and chemotherapy drug is highly 
cytotoxic. Pgp modulators belong to many different structural classes, and some are 
thought to act as alternative substrates for Pgp, engaging the protein in a futile cycle 
of ATP hydrolysis and transport. Clinical trials involving the Pgp modulator 
cyclosporin A have shown that acute myeloid leukemia patients who were treated 
with the modulator, as well as cytarabine and daunorubicin, had increased survival 
over patients treated with only standard chemotherapy drugs [47]. However, the use 
of modulators in cancer treatment has not generally been very successful [48]. Due to 
the variety of human tissues in which Pgp is normally found, the use of modulators 
can cause toxicity problems and needs to be carefully monitored. The toxicity and 
limited efficacy of Pgp modulators in vivo has hindered their use in the treatment of 
MDR cancers, and highlights the need for a greater understanding of the transporter. 
1.1.5 Clinical importance of p-glycoprotein 
1.1.5.1 Pgp-mediated in vivo drug-drug interactions 
A main focus of Pgp research thus far has been to reverse the Pgp-induced MDR 
phenotype in tumour cells, but with hundreds of potential substrates, there are 
numerous other clinical implications of Pgp expression. Pgp transports a wide variety 
of drugs used in the treatment of human diseases including anti-cancer drugs, 
antibiotics, HIV protease inhibitors, tyrosine kinase inhibitors, calcium channel 
blockers and cardiac glycosides. Simultaneously treating patients with different 
drugs is common practice, and with the ability of Pgp to affect the absorption, 
distribution and bioavailability of drugs, co-administration of multiple drugs that are 
Pgp substrates could have serious side effects [49]. The in vivo interaction of 
multiple drugs with Pgp can also be beneficial. Studies on Pgp knockout mice 
showed up to a 100-fold increase in central nervous system (CNS) penetration of 
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drugs [50], indicating that Pgp modulators could be used to enhance the treatment of 
neurological disorders by increasing drug access to the brain. 
Numerous adverse reactions have been observed in the clinic as a result of 
simultaneously treating patients with multiple Pgp substrates. Administration of the 
calcium channel blocker, mibefradil, and the immune suppressor, tacrolimus, to a 
liver transplant patient resulted in unexpected cognitive side effects, because both 
drugs interact with cytochrome P450 and are Pgp modulators [51]. Decreased 
metabolism of tacrolimus resulted in elevated blood levels that overwhelmed Pgp, 
and the drug passed through the BBB, causing CNS toxicity. Pgp expression in the 
brush-border of the small intestine normally prevents the absorption of numerous 
orally administered drugs. Administering rifampin with digoxin concomitantly 
resulted in a significant decrease in digoxin absorption, due to a 3.5 fold increase in 
Pgp expression caused by rifampin [52]. An increase in Pgp expression has also been 
observed after administration of St. John's wort [53], which is commonly found in 
over-the-counter herbal medications, demonstrating the potential for serious side 
effects if patients take herbal remedies in conjunction with drugs prescribed by their 
doctor. Due to the potential negative side effects of multiple drugs interacting 
simultaneously with Pgp, many compounds are now screened for Pgp transport 
ability during the drug discovery process. Drugs can be screened using in vitro and in 
vivo assays , as well as with computational methods based on in silico models of Pgp 
quantitative structure-activity relationships (QSAR) [54]. 
1.1.5.2 Overcoming Pgp-induced MDR in cancer therapy 
The overexpression of Pgp in tumour cells is one of the main causes of MDR, which 
is responsible for drug resistance in 50% of human cancers [41]. There was initial 
optimism that the use of Pgp reversal agents would allow oncologists to overcome 
the Pgp-induced drug resistance in MDR tumours. Although there has been some 
success using Pgp modulators to treat juvenile cancers, their use in clinical trials of 
adult cancers has been disappointing. The lack of efficacy of Pgp modulators in early 
clinical trials discouraged many pharmaceutical companies from further pursuing 
Pgp inhibition as a method of treating MDR [55]. A critical analysis of these studies 
indicates that their results may not be very reliable [45], and reveals a number of 
reasons why they failed to show a beneficial effect. One of the main problems was 
the lack of a consistent diagnosis of the MDR phenotype, resulting in the inclusion of 
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patients in the clinical trial who did not have drug resistance as a result of Pgp 
overexpression. 
First generation modulators (cyclosporin A, verapamil) were often 
pharmacologically active, and had low efficacy and high toxicity at clinically 
relevant doses, although some trials did show promising results [46]. Second 
generation modulators (PSC833 (valspodar)) were more efficacious at low doses and 
had no inherent toxicity, but many were substrates of cytochrome P450 3A. This 
resulted in adverse pharmacokinetic interactions, and increased toxicity in vivo when 
the treatment drug was also a P450 3A substrate. Problems with first and second 
generation modulators led to the careful design of third generation modulators 
(LY335979 (zosuquidar), GG918 (elacridar)) with low pharmacokinetic interactions 
and high affinity for Pgp. Currently, Phase I, II and III clinical trials involving third 
generation Pgp modulators are still under way. The results of well-designed Phase III 
clinical trials involving third generation modulators will be vital in determining if 
inhibition of Pgp can result in increased patient survival [55]. 
As an alternative to reversing MDR by suppressing Pgp function, it may be possible 
to exploit Pgp activity to induce cytotoxicity in MDR tumour cells. A 
thiosemicarbazone derivative (NSC73306) was identified in an NCI drug screen that 
looked for the potential interaction of candidate anti-cancer drugs with the 48 known 
human ABC proteins in the NCI-60 cell lines [56]. Surprisingly, compounds were 
identified whose activity increased rather than decreased in the presence of ABCB1. 
NSC73306 appears to interact with Pgp through an allosteric mechanism, and is 
cytotoxic to cells that overexpress Pgp either intrinsically, or through an acquired 
mechanism [57]. Administration of NSC73306 resensitized Pgp-expressing MDR 
carcinoma cells to other chemotherapeutic drugs, thus reversing the MDR phenotype. 
By selectively targeting MDR tumour cells that overexpress Pgp, NSC73306 
represents a novel way of reversing Pgp-mediated MDR, and may have an important 
clinical impact in cancer therapy [57]. 
The modulation of Pgp activity is an important step in the treatment of MDR cancers, 
but Pgp is not the only multidrug-binding ABC protein that contributes to in vivo 
drug resistance. The second generation Pgp modulator VX-710 (biricodar) has been 
shown to also inhibit the function of the multidrug transporters MRP1 (ABCC1) and 
BCRP (ABCG2), suggesting that it may be possible to develop agents with low 
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toxicity and high potency against all three proteins. To evaluate the in vivo effects of 
modulators, the radiopharmaceutical Tc-99m sestamibi, which is a Pgp substrate, has 
been used as an imaging agent. Tc-99m sestamibi allows clinicians to evaluate the 
efficacy of a modulator by monitoring changes in the in vivo uptake of a Pgp 
substrate. Despite early setbacks in the development and use of Pgp modulators, the 
importance of MDR in limiting the successful treatment of cancer demonstrates the 
need for continued research into ways of overcoming it. 
The use of modulators in combination with chemotherapy drugs has given promising 
results in vitro, but treatment success in vivo has been more difficult to obtain. The 
lack of success in clinical trials of Pgp modulators may be due to poor study design 
that did not account for Pgp single nucleotide polymorphisms (SNPs). More than 50 
SNPs (and insertion/deletion mutations) have been reported for ABCB1 [58], and 
recent studies have shown that a silent mutation in Pgp can result in changes in the 
binding affinity of substrates, likely by altering the kinetics of protein folding [59] 
1.2 Pgp Structure and Topology 
The human Pgp (product of the MDR1 gene; ABCB1) has 1280 amino acids that are 
arranged as two homologous halves joined by a linker region. Each half begins with 
a transmembrane domain (TMD) containing six transmembrane (TM) segments 
followed by a hydrophilic region containing a nucleotide-binding domain (NBD or 
ABC) (see Figure 1.2) [8,60,61]. The presence of four domains and conserved 
sequences in the NBDs are characteristic of the ATP-binding cassette (ABC) family 
of transporters [62]. The proposed topology of Pgp (Figure 1.2A) was first confirmed 
through the use of Cys mutagenesis [61] and epitope insertion with 
immunofluorescence. 
Several low-to-medium resolution electron microscopic images have been reported 
for Pgp, [63-66] the best of which is a ~8 Å cryo-electron microscopy structure with 
bound AMP-PNP [66]. The ~8 Å structure is important because it give us some 
opinion about nucleotide bound state of p-glycoprotein. This nucleotide bonded Pgp 
is very similar with Sav1866 (see 1.1D) [67] bound to ADP structure. This structure 
confirms the presence of two closely associated NBDs and TMDs consisting of 12 
helices in total, which reorient upon ATP binding. But cross-linking experiments 
have shown that TM helix 6 is close to TM10, 11, and 12, and that TM helix 12 is  
 
10 
 
 
Figure 1.2 : Structure of Pgp: A) The white cylinders represent the TM segments in 
TMD1, while the grey cylinders represent TM segments within TMD2. 
The branched lines represent the glycosylation sites and the rectangles 
represent the NBDs. B) Carton representation p-glycoprotein (pdb 
3G60). Symmetrical α-helices represented by similar color. C) View of 
the NBDs shown from the cytosol looking up toward the membrane. 
close to TM4, 5, and 6 [68]. From Cys mutagenesis studies, the drug-binding sites of 
Pgp appear to reside in the membrane-embedded region, at the interface between the 
two halves of the protein, in TM helices 4−6 and 9−12 [69-73]. Fluorescence studies 
have confirmed that the NBDs of Pgp are closely associated [74] and lie close to the 
membrane surface,[75] and showed that the drug-binding sites reside in the region of 
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the protein located in the inner leaflet of the membrane [76,77]. A recent study used 
cysteine mutagenesis and chemical cross-linking to show that Pgp shares important 
features of its domain architecture with Sav1866; in particular, the long intracellular 
loops of one TMD appeared to contact the opposing NBD, a feature not observed in 
bacterial ABC importers [78]. 
An important development in our understanding of mammalian ABC drug pumps 
was the recent publication of the 3.8 Å crystal structure of mouse Pgp in the absence 
of nucleotide [16] (Figure 1.2 B and C). The most remarkable feature of this “apo” 
structure is how well it agrees with both the bacterial ABC protein structures and the 
biochemical/biophysical data generated on Pgp structure and function over the past 
30 years [79]. The structure of Pgp ( Figure 1.2) represents a nucleotide-free inward-
facing conformation arranged as two “halves” with pseudo two-fold molecular 
symmetry spanning ~136 Å perpendicular to and ~70 Å in the plane of the bilayer. 
The nucleotide-binding domains (NBDs) are separated by ~30 Å. The inward-facing 
conformation, formed from two bundles of six transmembrane helices (TMs 1 to 3, 
6, 10, 11 and TMs 4, 5, 7 to 9, 12), results in a large internal cavity open to both the 
cytoplasm and the inner leaflet [16]. This crossover is very reminiscent of the 
Sav1866 (Figure 1.1 D) and corrected MsbA structures [80]. The Pgp structure was 
solved in the absence of nucleotide, and the two NBDs are located ~30 Å apart 
(Figure 1.2 A). The open-apo structure of MsbA from E. coli displays a much wider 
separation of the NBD domains. In contrast, one apo structure and the nucleotide-
bound MsbA structures, as well as the structures of Sav1866 (both nucleotide-bound 
[17,67]) and other bacterial ABC proteins, [23,81] show a tight association of the 
NBDs. The arrangement of the NBDs is already controversial, since some evidence 
supports the wide apo-MsbA structure [82-84]. It remains unclear whether such an 
open structure exists for native MsbA, since it would require a dramatic 
conformational change to close the NBDs upon nucleotide binding/hydrolysis. While 
the NBD separation is only 30 Å in the Pgp structure, versus ~50 Å in MsbA, Aller 
et al. suggest that Pgp may open even wider to accommodate very large substrates 
[16]. Further work will be required to distinguish whether this open conformation is 
a real feature of native Pgp or a crystal-packing artifact. 
The crystal structure of Pgp has some missing residues [16]. The N-terminus 
(residues 1-33) was not visualized and no electron density was present for most of 
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the linker region (residues 627-683), which is likely a flexible region connecting the 
two halves of Pgp [85]. Interestingly, both full-length Pgp and co-expressed half-
molecules of Pgp devoid of the linker region (Δ627-683) share similar drug-
stimulated ATPase activity suggesting that an intact linker is not required for drug-
coupled ATPase hydrolysis [86]. 
1.3 Interaction of Pgp With Substrates, Modulators and Nucleotides 
1.3.1 Drug binding 
1.3.1.1 Substrate specificity 
Pgp shows broad substrate specificity, recognizing hundreds of compounds as small 
as 330 daltons up to 4000 daltons [87,88]. In general, Pgp substrates tend to be large, 
hydrophobic, amphipathic molecules with aromatic rings and a positively-charged 
nitrogen atom [10-89], but these are not absolute requirements. However, it is 
difficult to make generalizations about the properties of compounds that interact with 
Pgp, and many substrates have been identified that do not strictly conform to these 
descriptors. For example, a variety of linear and cyclic peptides and ionophores are 
known to interact with the protein [90-92],  yet peptides are smaller than typical 
substrates and often lack aromatic rings. Pgp substrates include classical 
chemotherapeutic drugs (such as anthracyclines, Vinca alkaloids, and taxols), new 
classes of anticancer agents such as tyrosine kinase inhibitors, human 
immunodeficiency virus (HIV) protease inhibitors, immunosuppressants, ionophores, 
peptides, fluorescent dyes, steroids, cardiac glycosides, and many others (see Table 
1.1 ) [79]. There is a variation in the binding affinity (Kd of Pgp for drugs that covers 
4 orders of magnitude [17], indicating that the protein is able to distinguish between 
different substrates. 
Substrates are thought to interact with Pgp via hydrogen bonding, as well as 
hydrophobic and van der Waal's interactions, in a large, flexible, substrate binding 
pocket. Based on FRET mapping studies, the binding pocket is thought to be located 
in the cytoplasmic leaflet of the TM region of the protein [76,77]. It has been 
proposed that drugs bind to Pgp by an induced-fit type of mechanism [93], in which 
substrates enter the substrate binding pocket and create their own specific drug 
binding site using residues from a number of different TM helices. This mechanism  
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Group Compound 
analgesics morphine 
antiarrhythmics amiodarone, propafenone,quinidine 
antibiotics erythromycin, gramicidinD 
anthracenes bisantrene, mitoxantrone 
anthracyclines doxorubicin, daunorubicin 
camptothecins topotecan 
epipodophyllotoxins etoposide, teniposide 
taxanes paclitaxel,docetaxel 
Vincaalkaloids vinblastine, vincristine 
antiemetics ondansetron 
antiepileptics felbamate, topiramate 
antihelminthics ivermectin 
antihistamines fexofenadine, terfenadine 
antihypertensives reserpine, propanolol 
antiviraldrugs nelfinavir, ritonavir, saquinavir 
calcium-channelblockers azidopine, diltiazem, nifedipine, verapamil 
calmodulinantagonists chlorpromazine, trans-flupentixol 
cardiacglycosides digoxin 
fluorescentdyes calcein-AM,Hoechst 33342, rhodamine 123, 
 tetramethylrosamine 
H2-receptorantagonists cimetidine 
HMG-CoAreductaseinhibitors lovastatin, simvastatin, atorvastatin 
immunosuppressiveagents cyclosporinA, tacrolimus(FK506) 
naturalproducts colchicine, curcuminoids 
pesticides 
N-acetyl-LLY-amide(ALLN), leupeptin, 
pepstatinA, 
 valinomycin 
pesticides cypermethrin,endosulfan, fenvalerate, 
 methylparathion 
steroids 
aldosterone,corticosterone, cortisol, 
dexamethasone 
tyrosinekinaseinhibitors gefitinib, imatinibmesylate 
antialcoholismdrugs disulfiram 
 
explains how mutations at specific residues alter the binding affinity of Pgp for one 
substrate, but have no effect on the affinity for other substrates [94]. 
There have been attempts to associate the “affinity” of a Pgp substrate or modulator 
with its physical, chemical or structural properties through the use of QSARs. The 
search for specific structural characteristics common to all Pgp substrates has met 
with limited success. There is no common “pharmacophore” that can be used to 
identify a particular drug as a Pgp substrate [79]. The best general description of a 
Table 1.1: Chemotherapeutic Drugs and Other Compounds That Interact with p-
glycoproteins [79]. 
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Pgp substrate is that it contains 2 or 3 electron donor (hydrogen bond acceptor) 
groups with a fixed spatial separation [95,96]. Seelig and co-workers examined over 
100 compounds known to interact with Pgp and classified them based on the number 
and separation distance of electron donor groups. All substrates examined were 
found to possess either 2 or 3 electron donor groups separated by 2.5 or 4.6 Å. Other 
researchers subsequently suggested combinations of electron donors, hydrophobic 
groups, and/or aromatic rings in specific spatial organizations [97-99]. A more recent 
3-dimensional approach suggested that molecules with two H-bond acceptors 11.5 Å 
apart and two H-bond donors 16.5 Å apart would be Pgp substrates [100]. TM 
regions of Pgp thought to be involved in drug binding contain a large proportion of 
amino acid side chains that can act as hydrogen bond donors, facilitating interaction 
with substrate electron donor groups [95]. The fluorescence properties of aromatic 
Trp residues in Pgp are sensitive to substrate binding [101], and may be involved in 
stacking interactions between drug substrates and aromatic side chains in the Pgp 
drug binding pocket [102]. 
1.3.1.2 Nature of the drug binding site 
Pgp appears to have a large flexible binding region that can accommodate a wide 
range of compounds, rather than one or more well-defined binding sites. Two 
“functional” binding sites have been identified based on the transport of the drug 
substrates rhodamine 123 (R-site) and Hoechst 33342 (H-site) [103]. Two drugs that 
bind to the same site (either the H-site or the R-site) are proposed to show mutual 
inhibition of transport, whereas drugs that bind to different sites are proposed to 
exhibit mutual stimulation of transport. Using FRET, the locations of the H-site [76] 
and the R-site [77] have been mapped, and both are found within the cytoplasmic 
leaflet of the membrane. Analysis of the fluorescence characteristics of drugs bound 
to the H and R binding sites has shown that they are very hydrophobic in nature, with 
a polarity lower than chloroform [93], making it unlikely that the binding pocket is 
open to an aqueous chamber as previously suggested [64,104]. Crosslinking studies 
involving the insertion of Cys residues into Cys-less Pgp suggested that the substrate 
binding pocket is formed at the interface between the two TMDs, and involves TM 
helices 4, 5, and 6 in the N-terminal half of Pgp, and TM helices 9, 10, 11 and 12 in 
the C-terminal half [72]. The Pgp drug binding pocket is thought to be funnel-
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shaped, based on both cross-linking and EM studies [16], and appears to be narrower 
on the cytoplasmic side where TM2-TM11 and TM5-TM8 come together [105]. 
Using 3-D models of Pgp substrates, Garrigues and coworkers identified two 
different, overlapping pharmacophores in the protein [106], which may correspond to 
the H and R functional binding sites. This study suggested that it was possible for 
either two smaller substrates to bind to Pgp at the same time, or one larger substrate 
to occupy both pharmacophores. A recent homology model of Pgp in the post-
hydrolysis state, based on Savl866 [107], identified three main drug binding regions; 
one at the cytosolic interface of the membrane, and two located within the TM 
helices of the TMDs. In addition, a large central binding pocket was identified that 
contained residues from all three regions, which is thought to represent a low affinity 
“escaping” site from which substrates are released [107]. In the absence of high 
resolution structural data for Pgp with bound substrates, homology models can give 
insight into the specific molecular interactions that might take place in the drug 
binding pocket 
1.3.2 Nucleotide binding and hydrolysis 
The NBDs of ABC transporters are divided into two domains, the catalytic domain 
and the helical domain, which are connected via the Q-loop and the Pro-loop [108]. 
The catalytic domain contains the Walker A and B motifs, as well as the H-loop and 
D-loop, while the helical domain contains the ABC signature C motif. The binding of 
ATP to ABC proteins requires the Walker A and B motif of one NBD, along with the 
C motif of the partner NBD (see Figure 1.3). Thus, two ATP molecules are bound to 
each ABC protein, at the interface between the NBDs. The C motif interacts 
specifically with the γ-phosphate moiety of ATP, allowing for stable dimerization of 
the NBDs when ATP is bound, but not when ADP is present. Close association of the 
NBDs in the absence of nucleotide would facilitate dimer formation upon ATP 
binding, and has been seen in the crystal structures of several ABC proteins [15, 80, 
109]. Cryo-EM [64,66,110] and biochemical studies of Pgp [74,111] have also 
suggested close association of the NBDs. 
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C-Loop
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D-Loop
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(Walker B)
(LSGGQ)
 
Figure 1.3 : Nucleotide binding domain: The X-ray crystal structure of the NBDs of 
the bacterial MJ0796 ABC ATPase dimer (1L2T.pdb) with bound 
nucleotide. The conservative motifs (Walker A, B, C-Loop, D-Loop, H-
Switch) are showed on cartoon representation. 
Mutational analysis of the NBDs has identified a number of key residues that are 
involved in nucleotide binding and hydrolysis. The crystal structure of the 
catalytically inactive E171Q mutant of the NBD subunit MJ0796 first showed the 
formation of a nucleotide sandwich dimer through the stable binding of two ATP 
molecules [112]. A similar structure was observed for the NBDs of HlyB [113]. 
Corresponding mutations of Glu residues in mouse abcbla Pgp (E552A/El197A) 
resulted in tight occlusion of bound nucleotide at one NBD, and almost complete 
inhibition of ATPase activity [114]. This mutation abolished enzymatic activity by 
inhibiting formation of the catalytic transition state. Mutations of Ser (S430/S1073) 
or Lys (K429/K1072) residues in the Walker A motifs were also shown to be 
involved in reducing catalytic turnover, and allowed ATP binding, but inhibited 
occlusion [115]. The Q-loop is thought to be involved in communication between the 
substrate binding pocket and the catalytic sites, and mutations in the Q-loop Gin 
residues (Q471/Q1114) greatly reduced the stimulation of ATPase activity by 
verapamil [116]. Mutation of the conserved His residue in the H-loop (H662A) of 
HlyB resulted in a loss of ATPase activity, and has been proposed to be the 
“linchpin” of catalytic activity [117]. 
The TMDs of ABC proteins contain α-helical motifs that are embedded in the 
surface of the NBDs, at the interface between the helical and catalytic subdomains, 
and are essential for transmitting conformational changes between the NBDs and 
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TMDs. These coupling helices share little sequence similarity, but when bound to the 
NBDs their structures are very similar when superimposed upon one another 
[15,109]. The binding of the coupling helices to the NBDs differs for ABC importers 
and exporters. In exporters (Savl866 and MsbA), the TMD of one subunit interacts 
with the NBD of the opposing subunit, resulting in tight association of the NBDs, 
and a twisted conformation [17,80]. In contrast, the coupling helices of ABC 
importers (ModB2C2A, BtuCD, HI1470/71, maltose permease) are not swapped with 
the NBDs, resulting in a large gap at the centre of the transporter [15,109]. The 
coupling helices provide evidence for a common transport mechanism for all ABC 
proteins. The binding of substrate to an ABC protein, which occurs through 
interactions with an extracellular binding protein in importers, facilitates ATP 
hydrolysis by bringing the NBDs and coupling helices together, resulting in the 
protein transitioning from an inward-facing conformation to an outward-facing 
conformation [81,109]. ATP hydrolysis is thought to cause a reorientation of the TM 
helices that disrupts protein-substrate interactions, and results in substrate 
translocation. According to this model, translocation would occur in importers after 
the release of ADP and Pi resets the protein back to the inward-facing conformation 
[109], whereas in exporters, translocation would occur before the release of ADP and 
Pi. 
The binding to Pgp of a variety of nucleotides has been characterized, including 
ADP, ATP, their fluorescent derivatives 2'(3')-0-(2,4,6-trinitrophenyl)adenosine 5'-
diphosphate (TNP-ADP) and 2'(3')-0-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate 
(TNP-ATP), as well the non-hydrolysable nucleotide analogues AMP-PNP and ATP-
γ-S. The binding affinities of ADP, ATP, and AMP-PNP to Pgp are all quite similar 
(Kd -0.2- 0.4 mM) [101, 118], whereas the fluorescent nucleotides TNP-ADP and 
TNP-ATP bind to Pgp with a much higher affinity (Kd ~5 μM) [119]. The tight 
binding of TNP-labelled nucleotides is likely due to interactions of the hydrophobic 
trinitrophenyl group with nonpolar regions of Pgp. The non-hydrolysable analogue 
ATP-γ-S binds to Pgp with an even higher affinity than the fluorescent nucleotides 
(Kd -5 μM), and when bound to the protein may induce the formation of the occluded 
state [120]. ATP occlusion had previously been demonstrated only for catalytically 
deficient Pgp mutants. Purified Pgp generally demonstrates a high basal level of 
ATPase activity in the absence of substrate, although protein preparations from some 
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groups have very low basal ATPase activity, and need to be reactivated by adding 
lipids or reducing agents. These preparations often show a much higher fold-increase 
in drug stimulated ATPase activity due to an underestimation of the true potential 
basal activity [121]. 
It is thought that hydrolysis of ATP at the NBDs of Pgp occurs by an alternating sites 
mechanism, in which only one of the two catalytic sites is active at any time [122]. 
Communication between the two NBDs is facilitated by the D-loop, which enables 
alternating catalysis of ATP by transmitting information between the NBDs via the 
H-loop [117]. Both catalytic sites need to be functional for transport to occur as 
indicated by studies in which ATPase activity was abolished when mutations were 
made at one of the NBDs [123]. Pgp is able to bind two ATP molecules at once 
[124,125], but there has been debate over whether one or two molecules of ATP are 
hydrolyzed during the transport cycle. There has been a proposal that there are two 
rounds of ATP hydrolysis, with the first round driving substrate translocation, and 
the other responsible for resetting the protein for subsequent transport [126,127]. 
However, it has been demonstrated that there is an asymmetric occlusion of ATP 
during the catalytic cycle, with a stoichiometry of 1 [115,128] which would indicate 
that one ATP is hydrolyzed per transport cycle, as proposed in the original 
alternating sites mechanism. 
1.4 Transport Mechanisms of Pgp 
1.4.1 Hydrophobic vacuum cleaner and flippase models 
The majority of Pgp substrates are hydrophobic, indicating they likely first partition 
into the membrane bilayer before interacting with the protein. The location of the 
substrate binding sites of Pgp have been mapped in the cytoplasmic leaflet of 
membrane bilayer [76,77], supporting the idea that Pgp substrates must first partition 
into the membrane before they can bind to the protein. Many Pgp substrates have 
high lipid-water partition coefficients (Plip), which is consistent with this idea. Drugs 
with a high Plip tend to have a high affinity (low Kd) for binding to Pgp [129]. Once 
drugs have partitioned into the membrane, they move into the substrate binding 
pocket of Pgp in a process that is nearly isoenergetic [130], possibly through gates at 
the interface of the two TMDs, formed by TM helices 2 and 11 at one end of Pgp, 
and helices 5 and 8 at the opposite end [105]. 
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Two similar, but distinct mechanisms have been proposed for Pgp-mediated drug 
efflux; the hydrophobic vacuum cleaner model, and the flippase model [131]. It has 
been proposed that Pgp acts as a hydrophobic vacuum cleaner that binds drugs 
somewhere within the membrane and expels them to the extracellular medium. The 
flippase model is compatible with the hydrophobic vacuum cleaner model, and 
proposes that Pgp is a flippase that binds drugs in the cytoplasmic leaflet of the 
membrane and flips them to the extracellular leaflet. Attempts to distinguish between 
these two models have been inconclusive, as it is difficult to determine whether 
drugs are transported directly to the extracellular medium, or merely to the 
extracellular leaflet of the membrane, because drugs can partition very rapidly 
between the two locations. 
1.4.2 Catalytic cycle 
The catalytic cycle of Pgp involves the coupling of ATP binding and hydrolysis with 
substrate translocation across the cell membrane. Reactions taking place at the NBDs 
during the catalytic cycle include ATP binding and formation of a nucleotide 
sandwich dimer, followed by ATP hydrolysis, Pi dissociation, and finally ADP 
dissociation. For substrate translocation, drugs bind in the substrate binding pocket 
located in the inner leaflet, and conformational changes in the TMDs transport the 
substrate across the membrane where it is released. ATP binding, ATP hydrolysis 
and the release of ADP/Pi have all been shown to result in conformational changes in 
the protein [132], suggesting that energy is released at each of these steps. 
Crosslinking studies have shown that substrate binding induces changes in the 
packing of the TMDs [73]. Covalent coupling of the TMDs reversibly abolished 
ATPase activity [133], suggesting that nucleotide hydrolysis at the NBDs is coupled 
to substrate translocation via rotation or displacement of the TMDs. 
How ATP binding and hydrolysis drives the transport of Pgp substrates has been the 
subject of much debate. The binding of drugs can result in stimulation or inhibition 
of the ATPase activity of Pgp, with some drugs showing a biphasic pattern, with 
stimulation at low concentrations and inhibition at higher concentrations [134]. The 
presence of both a high-affinity stimulatory drug binding site, and a low-affinity 
inhibitory drug-binding site could explain the biphasic pattern [135]. Drugs that 
stimulate ATPase activity cause the Walker A residues of one half of Pgp to move 
closer to the LSGGQ motif of the other half [136], and promote occlusion of ATP at 
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one NBD [115], facilitating ATP hydrolysis. The establishment of a nucleotide 
sandwich dimer appears to be an important step in the catalytic cycle of Pgp, but 
there is still debate as to whether it is the binding of ATP, or ATP hydrolysis itself 
that drives the transport of substrates, and whether drug binding stimulates ATP 
binding and dimerization of the NBDs. 
One proposed model for drug translocation by Pgp is the ATP switch model [137], in 
which resting state Pgp would have high affinity for substrates and low affinity for 
ATP. Substrate binding initiates communication with the NBDs, resulting in the 
binding of two ATP molecules. ATP binding induces NBD dimerization, with 
corresponding changes in the TMDs that result in substrate translocation by exposing 
the substrate to the extracellular environment, where the TMDs have low affinity for 
substrate. ATP hydrolysis at one or both NBDs, followed by release of ADP and Pi, 
resets Pgp back to its resting state. Although this model claims to be supported by 
available biochemical data, it makes numerous assumptions based on the 
photoaffinity labelling technique, which has been shown to be an unreliable method 
for measuring binding affinity [138]. Pgp drug substrates are clearly not required for 
NBD dimerization, as Pgp can bind and hydrolyze ATP in the absence of substrates 
[121]. It has also been demonstrated that the rate-limiting step of transport is ATP 
hydrolysis, which is associated with a reorientation of the drug binding site from a 
high-affinity state to a low affinity state [139], indicating that ATP binding does not 
cause substrate translocation as proposed in this model. While the ATP switch model 
attempts to provide a generalized transport mechanism for all ABC proteins, it is 
inconsistent with biochemical data available for Pgp, and does not adequately 
explain the catalytic cycle of this protein. 
Orthovanadate (Vi) is a phosphate analogue that has helped give insight into the 
catalytic cycle of Pgp. Vi can reversibly replace Pi in a single active site after ATP 
hydrolysis, trapping Pgp in a stable complex. The vanadate trapped Pgp-ADP-Vi-
M2+ (where M2+ is a divalent cation) still has one free NBD, but displays no ATPase 
activity [140], and is thought to have a structure that resembles the catalytic 
transition state. The complex is stable for >3 h when trapped in the presence of 
Co2+ [125], allowing for detailed studies with fluorescence spectroscopy, before slow 
dissociation of Vi, and subsequently ADP, results in full restoration of ATPase 
activity. Vanadate-trapped Pgp has been shown to have a substrate binding affinity 
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similar to that of native Pgp, indicating that ATP hydrolysis, rather than the release 
of ADP, resets the transporter back to its resting state [141]. Crosslinking studies 
show that the vanadate-trapped state has different residues accessible to crosslinkers 
compared to nucleotide-free Pgp [142], suggesting that although Pgp-ADP-Vi-
M2+ has normal affinity for substrates, some TM helix rotations are still required for 
the protein to regain its native conformation [143]. 
Detailed biochemical studies of Pgp using spin-labelled substrates, and 
thermodynamic analysis at different stages of the catalytic cycle, led to the proposal 
of the partition model, in which Pgp has two distinct transition states [121]. One 
transition state corresponds to basal ATPase activity that is uncoupled from drug 
translocation, and the other state corresponds to coupled drug transport activity. If 
there is sufficient drug present, Pgp will partition into the drug-coupled transport 
cycle, in which substrate binding is followed by the binding of two ATP molecules, 
with occlusion and hydrolysis of one ATP by an alternating sites mechanism [122]. 
When no drug is present, and a second molecule of ATP binds, then the protein will 
partition into the uncoupled basal cycle. The rate-limiting step for both the basal 
cycle and drug-coupled cycle is ATP hydrolysis, and the energy released from 
hydrolysis of one ATP molecule is sufficient to forcibly rehydrate a bound drug 
molecule [121]. ATP hydrolysis is proposed to move substrates from a drug loading 
“ON-site” in the inner leaflet with high affinity for substrate, to a drug-unloading 
“OFF-site” in the extracellular leaflet with low affinity for substrate, resulting in 
transport of drug across the membrane. For drug substrates that show inhibition of 
ATPase activity at higher concentrations, free energy analysis demonstrated that this 
is not the result of a separate rate-limiting step, but likely the result of inhibition of 
drug release from the low affinity OFF-site. However, studies showing a permanent 
increase in ATPase activity after covalent crosslinking of methanethiosulfonate 
(MTS)-verapamil to the drug binding pocket suggest that drug release from the “ON-
site” is not required for ATPase stimulation [144]. 
The drug-coupled ATPase activity of various drugs displayed a linear free energy 
relationship, indicating that all drugs have the same rate-limiting transition step 
during the transport cycle. Basal ATPase activity has a clearly different free energy 
relationship from drug-coupled activity, suggesting that basal activity is not the result 
of either transport of an unidentified substrate, or nonspecific lipid-flipping, as 
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previously suggested [145]. Each drug makes unique molecular interactions with the 
transition state, and has a different intrinsic kcat value. Drugs that require fewer 
molecular rearrangements to achieve the transition state are transported faster, and 
therefore have a higher level of drug-coupled ATPase activity. This model explains 
how some drugs appear to stimulate ATPase activity, whereas others appear to have 
no effect. If the drug-coupled ATPase activity for a particular substrate is higher than 
the intrinsic basal ATPase activity, then biochemical assays will indicate that the 
drug causes a stimulation of ATPase activity. The partition model is currently the 
only model in the literature that can account for most of the kinetic data available for 
Pgp [146], and may explain the complex relationship between the catalytic and drug 
transport cycles of this enzyme. 
1.5 HMG-CoA Reductase Inhibitors (Statins) 
Elevated cholesterol levels are a primary risk factor for coronary artery disease. This 
disease is a major problem in developed countries. Dietary changes and drug therapy 
reduce serum cholesterol levels and dramatically decrease the risk of stroke and 
overall mortality. Inhibitors of HMGR, commonly referred to as statins, are effective 
and safe drugs that are widely prescribed in cholesterol-lowering therapy. In addition 
to lowering cholesterol, statins appear to have a number of additional effects, such as 
the nitric oxide–mediated promotion of new blood vessel growth [147] stimulation of 
bone formation [148], protection against oxidative modification of low-density 
lipoprotein, as well as anti-inflammatory effects and a reduction in C-reactive protein 
levels [149]. Based on the accumulation of evidence obtained in vitro and in clinical 
settings, statins are now being tried for other diseases, including Alzheimer's disease, 
cancer, and osteoporosis [150]. All statins curtail cholesterol biosynthesis by 
inhibiting the committed step in the biosynthesis of isoprenoids and sterols [151]. 
This step is the four-electron reductive deacylation of HMG-CoA to CoA and 
mevalonate. It is catalyzed by HMGR in a reaction that proceeds as follows; 
(S)-HMG-CoA + 2NADPH + 2H+ → (R)-meval + 2NADPH+ + CoASH 
where NADP+ is the oxidized form of nicotinamide adenine dinucelotide, NADPH is 
the reduced form of NADP+, and CoASH is the reduced form of CoA. 
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Several statins are available or in late-stage clinical development (Figure 1.4). All 
share an HMG-like moiety, which may be present in an inactive lactone form. in 
vivo, these prodrugs are enzymatically hydrolyzed to their active hydroxy-acid forms 
[151]. The statins share rigid, hydrophobic groups that are covalently linked to the 
HMG-like moiety. Lovastatin, pravastatin, and simvastatin resemble the substituted 
decalin-ring structure of compactin (also known as mevastatin). Fluvastatin, 
cerivastatin, atorvastatin, and rosuvastatin are fully synthetic HMGR inhibitors with 
larger groups linked to the HMG-like moiety. The additional groups range in 
character from very hydrophobic (e.g., cerivastatin) to partly hydrophobic (e.g., 
rosuvastatin). All statins are competitive inhibitors of HMGR with respect to binding 
of the substrate HMG-CoA, but not with respect to binding of NADPH [152]. The 
Ki (inhibition constant) values for the statin-enzyme complexes range between 0.1 to 
2.3 nM [151], whereas the Michaelis constant, Km, for HMG-CoA is 4 μM [153]. 
As statins come to be used more frequently to treat complicated diseases, one should 
use them more carefully paying attention to drug-drug interactions, which raise the 
risk of adverse events [154]. In 2001, cerivastatin was withdrawn from the market 
because of rhabdomyolysis found especially in patients coprescribed gemfibrozil. It 
has been proved that gemfibrozil elevated cerivastatin concentration with 5.6-fold for 
AUC of parent form and 4.4-fold for that of lactone form [155]. 
1.6 Role of P-glycoprotein on Statin Pharmacokinetics 
Atorvastatin [156] (acid [157-160], methyl ester [157], and lactone [157,161] forms), 
lovastatin (lactone form) [156,157,159,161,162] and simvastatin (acid [159] and 
lactone forms) [156,157,159,161,163] inhibit P-gp substrate transport in a 
concentration-dependent manner, [156-158,160] with high concentrations of 
atorvastatin needed in some studies [156,159,160]. 
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Figure 1.4 : Statins: Structural formulas of statin inhibitors and the enzyme substrate 
HMG-CoA. The HMG-like moiety that is conserved in all statins is 
colored in red 
Drug interactions have been reported between statins and Pgp substrates or 
inhibitors, including St. John's wort, digoxin, diltiazem, verapamil, itraconazole, 
grapefruit juice, cyclosporine, mibefradil, erythromycin, and clarithromycin [164] Of 
interest,great overlap exists between agents that are both CYP3A4 and Pgp substrates 
or inhibitors [165,166]. With the exception of digoxin, all other Pgp substrates or 
inhibitors are also CYP3A4 modulators [166,167]. Statins are generally regarded as 
CYP3A4 substrates; however, neither pravastatin nor rosuvastatin has been shown to 
be metabolized by CYP3A4 [167-169]. Pravastatin is enzymatically broken down in 
liver cells into inactive metabolites [168], and fluvastatin is metabolized 
predominantly by CYP2C9 [167]. An in vitro study showed that rosuvastatin was 
neither a substrate nor an inhibitor of CYP3A4 [169]. Coincidentally, fluvastatin 
(although partially metabolized by CYP3A4), pravastatin, and rosuvastatin have not 
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been shown to be a substrate or inhibitor of Pgp [164]. How much the drug 
interactions with simvastatin, lovastatin, and atorvastatin are due to CYP3A4 or Pgp 
modulation is unknown. However, since data suggest that these statins are Pgp 
substrates, both CYP3A4 and Pgp modulation may be involved in the interaction, 
causing an increase in serum concentrations of the respective statin. There is great 
opportunity to explore the precise mechanisms of these drug interactions. 
Interactions that were once thought to be purely related to CYP3A4 interactions may 
also be at least partly explained by Pgp-mediated interactions. 
1.7 Aim of The Study 
The purpose of this study is to investigate the interactions of Pgp with statins by the 
aid of molecular dynamic simulation and by using Atorvastatin as a model 
compound. 
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2.  METHODOLOGY 
2.1 Molecular Dynamics Simulation 
Biomolecular dynamics occur over a wide range of scales in both time and space, 
and the choice of approach to study them depends on the question asked. Molecular 
simulation is far from the only theoretical method; when the aim is to predict, e.g., 
the structure and/or function of proteins rather than studying the folding process, the 
best tool is normally bioinformatics that detect related proteins from amino acid 
sequence similarity; and, for computational drug design, often it is much more 
productive to use statistical methods such as quantitative structure–activity 
relationship (QSAR) instead of spending billions of CPU hours to simulate binding 
of thousands of compounds. 
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Figure 2.1 : Range of time scales for dynamics in biomolecular systems: Although 
the individual time steps of molecular dynamics is 1 to 2 fs, parallel 
computers make it possible to simulate on a microsecond scale, and 
distributed computing techniques can sample even slower processes, 
almost reaching milliseconds [170]. 
The most important point of simulations is that they provide a way to test whether 
theoretical models predict experimental observations. As an example, simulations of 
ion channels cannot compete with experiments when it comes to measuring ion 
currents, but they have been useful to explain why some ions pass whereas others are 
blocked. Similarly, simulations can provide detail not accessible through 
experiments, for instance, pressure distributions inside membranes. Further, 
structural refinement and energy minimizations are regularly used to improve both 
experimental and predicted protein structures, and drug design is moving toward 
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more accurate models, even including large-scale simulations for free energy 
screening. 
Ideally, the time-dependent Schrödinger equation should be able to predict all 
properties of any molecule with arbitrary precision ab initio. However, as soon as 
more than a handful of particles are involved, it is necessary to introduce 
approximations. For most biomolecular systems, we, therefore, choose to work with 
empirical parameterizations of models instead; for instance, classic Coulomb 
interactions between pointlike atomic charges rather than a quantum description of 
the electrons. These models are not only orders of magnitude faster, but because they 
have been parameterized from experiments, they also perform better when it comes 
to reproducing observations on a microsecond scale (see Figure 2.1), rather than 
extrapolating quantum models 10 orders of magnitude. The first molecular dynamics 
simulation was performed as late as 1957 [171], although it was not until the 1970s 
that it was possible to simulate water [172] and biomolecules [173]. 
2.2 Theory 
Macroscopic properties measured in an experiment are not direct observations, but 
averages over billions of molecules representing a statistical mechanics ensemble. 
This has deep theoretical implications, which are covered in great detail in the 
literature [174,175], but, even from a practical point of view, there are important 
consequences. 1) It is not sufficient to work with individual structures, but systems 
have to be expanded to generate a representative ensemble of structures at the given 
experimental conditions, e.g., temperature and pressure. 2) Thermodynamic 
equilibrium properties related to free energy, such as binding constant, solubilities, 
and relative stability, cannot be calculated directly from individual simulations. 3) 
For equilibrium properties (in contrast to kinetic), the aim is to examine the ensemble 
of structures, and not necessarily to reproduce individual atomic trajectories. 
The two most common ways to generate statistically faithful equilibrium ensembles 
are Monte Carlo and molecular dynamics simulations; the latter also has the 
advantage of accurately reproducing kinetics of non-equilibrium properties such as 
diffusion or folding times. When a starting configuration is very far from 
equilibrium, large forces can cause the simulation to crash or distort the system, and, 
in this case, it is necessary to start with energy minimization of the system before the 
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molecular dynamics simulation. In addition, energy minimizations are commonly 
used to refine low-resolution experimental structures. 
All classic simulation methods rely on more or less empirical approximations called 
force fields [176-179] to calculate interactions and evaluate the potential energy of 
the system as a function of point like atomic coordinates. A force field consists of 
both the set of equations used to calculate the potential energy and forces from 
particle coordinates, as well as a collection of parameters used in the equations. For 
most purposes, these approximations work well, but they cannot reproduce quantum 
effects such as bond formation or breaking. 
Bond
vibration
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Torsion
potentials
+ -
van der Waals interactions Electrostatics
 
Figure 2.2 : Examples of interaction functions in modern force fields: Bonded 
interactions include covalent bond-stretching, angle-bending, torsion 
rotation around bonds and out-of-plane or “improper” torsions (not 
shown). Non-bonded interactions are based on neighborlists and consist 
of Lennard-Jones attraction and repulsion as well as Coulomb 
electrostatics. 
All common force fields subdivide potential functions into two classes. Bonded 
interactions cover covalent bond-stretching, angle-bending, torsion potentials when 
rotating around bonds, and out-of-plane “improper torsion” potentials, all which are 
normally fixed throughout a simulation (see Figure 2.2).  The remaining nonbonded 
interactions consist of Lennard-Jones repulsion and dispersion as well as Coulomb 
electrostatics. These are typically computed from neighbour lists updated every 5 to 
10 steps. 
Given the potential and force (negative gradient of potential) for all atoms, the 
coordinates are updated for the next step. For energy minimization, the steepest 
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descent algorithm simply moves each atom a short distance in the direction of 
decreasing energy, while molecular dynamics is performed by integrating Newton’s 
equations of motion (see Equation 2.1) [180].  
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The updated coordinates are then used to evaluate the potential energy again, as 
shown in the flowchart of Figure 2.3. 
Typical biomolecular simulations use periodic boundary conditions to avoid surface 
artifacts, so that a water molecule that exits to the right reappears on the left; if the 
box is sufficiently large, the molecules will not interact significantly with their 
periodic copies. This is intimately related to the non-bonded interactions, which 
ideally should be summed over all neighbors in the resulting infinite periodic system. 
Simple cut-offs can work for Lennard-Jones interactions that decay very rapidly, but, 
for Coulomb interactions, a sudden cut-off can lead to large errors. One alternative is 
to “switch off” the interaction before the cut-off, but a better option is to use particle 
mesh Ewald summation (PME) to calculate the infinite electrostatic interactions by 
splitting the summation into short- and long-range parts [181]. For PME, the cut-off 
only determines the balance between the two parts, and the long-range part is treated 
by assigning charges to a grid that is solved in reciprocal space through Fourier 
transforms. 
Cut-offs and rounding errors can lead to drifts in energy, which will cause the system 
to heat up during the simulation. To control this, the system is normally coupled to a 
thermostat that scales velocities during the integration to maintain room temperature. 
Similarly, the total pressure in the system can be adjusted through scaling the 
simulation box size, either isotropically or separately in x, y, and z dimensions. 
The single most demanding part of simulations is the computation of non-bonded 
interactions, because millions of pairs have to be evaluated for each time step. 
Extending the time step is, thus, an important way to improve simulation 
performance, but, unfortunately, errors are introduced in bond vibrations already at 1 
fs. However, in most simulations, the bond vibrations are not of interest per se, and  
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Interaction function V(r)  - forcefields
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Figure 2.3 : Simplified flowchart of a typical molecular dynamics simulation: The 
basic idea is to generate structures from a natural ensemble by 
calculating potential functions and integrating Newton’s equations of 
motion; these structures are then used to evaluate equilibrium properties 
of the system. A typical time step is on the order of 1 or 2 fs! 
can be removed entirely by introducing bond constraint algorithms such as SHAKE 
[182] or LINCS [183]. Constraints make it possible to extend time steps to 2 fs, and 
fixed-length bonds are likely better approximations of the quantum mechanical 
grounds state than harmonic springs. 
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2.2.1 Potential energy function 
The backbone of the classical simulations is the potential energy function, a relation 
that expresses the energy of a molecular system as a function of its atomic 
coordinates [184]. 
A typical potential energy function has the form: 
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The first three terms are associated with covalently connected atoms, while the last 
two terms are for non-covalent on non-bonded interaction between atoms. The first 
term is a summation over energies associated with bond stretching between two 
covalently bonded atoms (1-2, two-body interactions), the second term represent the 
bending of bond angles(1-3 three-body interactions) while the third term represent 
torsions (1-4, four body interactions). In the fourth term, van der Waals interactions 
are described by a Lennard-Jones potential between atoms separated by distance rij. 
The fifth term is associated with electrostatic interactions, described as partial point 
charges interacting via Coulomb's law. Non-bonded pair interactions involving atoms 
that are covalently linked by one or a chain of two bonds (e.g. pairs 1-2 and 1-3) are 
normally excluded from the fourth and fifth terms. Terms in the equation are 
optimized to describe physical interactions that determine the structure and dynamic 
properties of the molecular system. Nuclei and electrons are treated together as 
spherical particles (atoms) with a net point charge. Atomic radii are determined from 
experiment structural data while bonds connecting atoms are modelled as harmonic 
springs with the ability to stretch, bend and twist as illustrated in Figure 2.2. 
Equation (2.2) represents the basic functional form of the potential energy function. 
Variants of this equation may have additional terms such as: an improper dihedral 
term to prevent out-of-plane distortions, mixed terms that directly couple stretching 
and bending in adjacent bonds, special hydrogen-bond terms to account for 
electronic polarizability etc [185]. These extensions are normally meant to increase 
accuracy or to tailor the function for specialized applications. The quest for increased 
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accuracy is, however, normally associated with increased computational cost. The 
values for bond lengths b, bond angles θ, torsion angles ψ and distance between 
atoms rij, are obtained from experimental X-ray or NMR structures of from modeled 
structures. The rest of the parameters in Equation (2.2) are optimized to reproduce 
experimentally known properties of the system or ab initio quantum data on small 
molecules. Experimental data use in fitting parameters include, densities, enthalpies 
of vaporization and free energies of solvation. The potential energy function, 
together with its associated set of parameters, constitute a “force-field”. Commonly 
used force-fields for simulating biomolecules include AMBER [186], CHARMM 
[177], GROMOS [187] and OPS [188]. Naturally, the choices of the force-field 
should be guided by the type of molecular system for which it has been 
parameterized. 
Following the choice of an appropriate force-field, the next task is to generate a set 
of low energy configuration of the molecular system to be used in statistical 
mechanical evaluation of macroscopic properties. 
2.3 Simulation Detail 
2.3.1 Simulation system design 
The initial systems (see Table 2.1 and Figure 2.4) was set up to explore the 
conformational dynamics of Pgp, an approximation of the physiological 
environment, whereby the entire protein is inserted into a solvated lipid (dimyristoyl 
phosphatidylcholine, DMPC) bilayer in a box of water. Then the system was 
explored with and without different substrates. For simulation ALLM (N-acetyl-lue-
leu-methinonal), AFMRF (N-acetyl-phe-met-arg-phe-al) linear peptide and lactone 
atorvastatin is used as substrates. 
 
34 
 
Figure 2.4 : Simulation system: Pgp is shown in surface representation. The Ppp 
complex is embedded in a DMPC bilayer, with headgroup phosphorus 
atoms in orange and the hydrophobic tails of the lipids in cyan. The 
hydrophobic residues of Pgp are colored gray. TYR and TRP (red) 
residues that positioned between and lipid and aqua phase charged 
residues (blue) that are generally positioned in aqua phase. 
Table 2.1:   Summary of simulations 
Simulation Components 
Number of 
atoms 
duration 
restrained 
(ns) 
duration 
unrestrained 
(ns) 
APO Pgp ~220,000 1.2 ns 10 ns 
ALLM 
Pgp + MgATP + 
ALLM ~220,000 1.2 ns 10 ns 
AFMRF 
Pgp + MgATP + 
AFMRF ~220,000 1.2 ns 10 ns 
AFMRF-noATP Pgp + AFMRF ~220,000 1.2 ns 10 ns 
LACAVA 
Pgp + MgATP + 
Lactone 
Atorvastatin 
~220,000 1.2 ns 10 ns 
 
2.3.2 System preparation and simulations 
Coordinate (PDB code 3G60 [16]) for Pgp were used and downloaded from the 
Protein Data Bank [189]. The only modification from the downloaded coordinates 
was the removal of the bonded inhibitor molecules from the Pgp structure. 
A pre-equilibrated DMPC bilayer of 128 lipid bilayer [190] is used to construct 512 
bilayer. The TMDs were inserted in this bilayer and oriented using bands of charged 
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residues to determine the optimal position of the protein relative to the bilayer. The 
protein is then oriented in such a way that its hydrophobic belt is aligned with the 
non-polar lipid tails [191]. DMPC molecules overlapping the protein were removed 
with g_membed [192] application, and the resultant Pgp/bilayer system was solvated, 
energy-minimized, and equilibrated for 5 ns, with the non-H atoms of the Pgp 
restrained (force constant ) 1000 kJ mol-1nm-1) in order to allow a relaxation of the 
packing of lipids around the protein. 
Polar hydrogens were added to the crystal structure of Pgp. A doubly protonated 
state was chosen for the side chain of each histidine residue in H-Switch  of NBD. 
Default protonation states were assumed for all other residues. 
 
Figure 2.5 : Docking of lactone atorvastatin: This figure represents binding pocket 
of lactone atorvastatin in Pgp. This binding pocket is found by docking 
and nearly same for all other used substrates. 
In order to generate the Pgp and substrate complex, it was necessary to dock the 
substrate into Pgp. Before docking, substrate was positioned in place of inhibitor 
position according to crystal structure. After this positioning of subsrate, Autodock 
and Autock Vina tools [193,194] were used to dock substrates. 
Mg2+-ATP was docked into the NBDs using the MJ0796 NBD dimer structure (PDB 
code 1L2T) as a template. The Na-ATP coordinates from MJ0796 were 
superimposed onto each Pgp by least-squares fitting of residues from the Walker A 
and Walker B motifs and the Q-loop. It was then assumed that the Mg2+ ion binds to 
the same coordinates as the Na+ ion. In the default ATP force field the γ-phosphate is 
singly protonated. We modified this by removing the hydrogen from the γ-phosphate 
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and redistributing the partial charges evenly over the phosphate oxygen atoms such 
that the overall charge of the MgATP is -2e. 
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Figure 2.6 : ATP Docking: Each ATP molecules are docked manually by represent 
characteristic all ABC transporters. All motifs have a role in positioning 
ATP molecule is represented in figure. Mg atom and coordination shell 
hydrogen bonding are represented by yellow dots. 
All energy minimization was performed using 100 steps of the steepest descents 
algorithm. Equilibration was performed using harmonic restraints on the protein non-
H atoms (and ATP when present) (force constant) 1000 kJ mol-1nm-1), a Berendsen 
thermostat [195], and pressure maintained at 1 bar by a Berendsen barostat [195]. 
The unrestrained production runs were performed with a Nose-Hoover thermostat 
([196-197] and pressure maintained at 1 bar by a Parrinello-Rahman barostat [198]. 
The simulations were run in the NPT ensemble and at a temperature of 310 K. 
Particle mesh Ewald (PME) was used to treat long-range electrostatics [199], and the 
single point charge (SPC) water model [200] was used for the solvent. Chloride 
anions were positioned randomly among the solvent to neutralize the system. The 
integration time step was 2 fs, and coordinates were saved every 5 ps for subsequent 
analysis. The LINCS algorithm was used to restrain all bond lengths [183]. 
Simulations were run and analyzed using the GROMACS v. 4.0.5 
(http://www.gromacs.org) molecular dynamics simulation package [201-203] with 
the GROMOS96 united-atom forcefield [178,187]. Lipid parameters were based on 
those described in [190]. Pore profiles were calculated using CAVER [204]. 3D 
graphics were produced using VMD [205] and PyMol [206]. 
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2.4 Analysis Method 
The positions and velocities of every atom of a simulation system are specified for 
every time step by the simulations trajectory. The structural changes of a protein can 
thus be obtained from such a trajectory, and are characterized by the methods 
introduced below. 
2.4.1 Root mean square deviation 
The root mean square deviation (RMSD) of a structure with atomic coordinates 
ri with respect to a reference structure with its atoms coordinates 0ir  yields a 
quantitative measure for the structural difference between both, 
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The definition of the RMSD requires the rotation and translation of the structure 
towards its best fit to the reference structure. The calculation of an appropriate 
RMSD of a proteins structure along its trajectory with respect to its crystal structure, 
e.g., yields a measure for conformational changes. Typically, an RMSD of 2–3 Å is 
caused by thermal fluctuations, whereas larger values point towards conformational 
changes. 
To obtain information about the globular motion of the structure, a subset of atoms 
from the system is chosen for the calculation of the RMSD via Equation (2.3). This 
subset consists out of the amino acid backbone atoms, due to the noise induced by 
the fluctuations of amino acid side-chains. However, if a certain region in the protein 
is expected to contribute strongly to the total RMSD, a subset of atoms from that 
particular region can be used to calculate a more specific RMSD of that region. 
Even though the RMSD can indicate general motions or conformational changes, the 
specific motions in phase space cannot be exactly determined. It is, therefore, not 
possible to correlate the globular motions of a protein from two ore more 
independent trajectories by their respective time resolved RMSD. 
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2.4.2 Principal component analysis 
One major technique to extract and classify information about large conformational 
changes from an ensemble of protein structures generated either experimentally or 
theoretically, is principal component analysis (PCA). A detailed mathematical 
description of PCA is given in ref. [180,207]. Principal component analysis is based 
on the observation that the largest part of positional fluctuations in biomolecules, like 
proteins, occurs along a small subset of collective degrees of freedom. The presence 
of a large number of internal constraints, defined by the atomic interactions in a 
biomolecule, leads to the dominance of this small subset of degrees of freedom 
(essential subspace) in the molecular dynamics of a protein. In particular, these 
interactions range from the strong covalent bonds to the weaker non-bonded 
interactions. PCA identifies the collective degrees of freedom that most contribute to 
the total amount of fluctuations. Typically, a small subset of 5–10% of the total 
degrees of freedom accounts for more than 90% of the total fluctuations within a 
protein [207-209]. 
In general, PCA can be regarded as a multi-dimensional linear least squares fit 
procedure in configuration space. After fitting each configuration to a reference 
structure, the covariance matrix of the atoms positional fluctuations is build and 
diagonalized, 
  TRtRRtRC  )()(  (2.4) 
where R(t) resembles the fitted ensemble (e.g. from a MD trajectory) of internal 
motions and  an ensemble average. Here, R is a column vector of size 3N, 
describing the coordinates of N atoms, and thus representing every structure of the 
ensemble. Because the collective motions of a protein are described very well by 
their backbone motions, the covariance matrix was made up by the proteins 
backbone atoms in this work. The sym-metric 3Nx3N matrix C is diagonalized by an 
orthogonal coordinate transformation D, containing the eigenvalues λi of matrix C. 
The ith column of D contains the normalized eigenvector, i.e. principal component, 
μi of matrix C corresponding to λi. 
The eigenvalues λi describe the mean square fluctuations along the respective 
eigenvector μi .Hence, they contain each principal component’s contribution to the 
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total fluctuation. Sorting the eigenvectors μi according to their corresponding 
eigenvalue λi from large to small, therefore, yields a description of the collective 
motions of the system by the first eigenvectors. 
These principal components comply with collective coordinates, including 
contributions from every atom of the protein, and were shown to make up for the 
functional dynamics of proteins in several cases [207,210]. 
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3.  RESULTS and DISCUSSION 
3.1 Equilibration of Lipid Bilayer 
Before Pgp simulation the lipid bilayer was prepared and analysed whether or not 
represent real system. The 512 DMPC (1,2-dimyristoyl-sn-glycero-3-
phosphocholine) bilayer was constructed by using 128 pre-equilibrated 128 lipid 
bilayer. After energy minimization of bilayer, the system was simulated for 1ns and 
analysed. These analyses are: 
 The area per lipid of lipid bilayer was calculated from the lateral x and y 
dimensions of the simulation box divided by the number of lipid molecules in 
one leaflet of the bilayer. The Figure 3.1 shows the area per lipid value of 
prepared lipids. The value of area per lipid was equilibrated about 0.62 and 
this value is acceptable with compared experimental value of 0.606 [211]. 
 The deuterium order parameter SCD for the carbon tails is calculated from the 
elements of the order parameter tensor Sxx = 1/2 2/)1cos3(
2 i  and 
Syy as SCD = 2/3Sxx + 1/3Syy. The angle αi is the angle between the molecular 
axis given by the carbon atoms Ci−1 and Ci+1 and the lipid bilayer normal; the 
average is taken over the time of 0-10 ns and for all lipid molecules. 
Calculations have been performed with the g_order program of the 
GROMACS suite. 
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Figure 3.1 :  Area per lipid of DMPC. Area per lipid ratio dependent on MD 
simulation time for a 512-molecule lipid bilayer obtained for DMPC. 
The experimental value of area per lipid for DMPC is 0.606 [211]. 
Although the lipid bilayer structure is quite stable, its individual phospholipid and 
sterol molecules have some freedom of motion. The structure and flexibility of the 
lipid bilayer depend on temperature and on the lipid types. At relatively low 
temperatures, the lipids in a bilayer form a semisolid gel phase, in which all types of 
motion of individual lipid molecules are strongly constrained; the bilayer is 
paracrystalline. At relatively high temperatures, individual hydrocarbon chains of 
fatty acids are in constant motion produced by rotation about the carbon-carbon 
bonds of the long acyl side chains. In this liquid-disordered state, or fluid state, the 
interior of the bilayer is more fluid than solid and the bilayer is like a sea of 
constantly moving lipid. At intermediate temperatures, the lipids exist in a liquid-
ordered state; there is less thermal motion in the acyl chains of the lipid bilayer, but 
lateral movement in the plane of the bilayer still takes place. According to Figure 3.2 
bilayer the lipids gets into liquid-ordered state and represents in-vivo environment. 
This lipid bilayer is used for inserting Pgp. After each Pgp simulation these 
parameters (area per lipid, deuterium order parameters) were checked for stability of 
lipid bilayer. 
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Figure 3.2 :   Deuterium order parameters of DMPC bilayer. Comparison of the 
deuterium order parameters along the carbon atoms of the lipid acyl 
tails from simulation (*) and those from experimental results (+). The 
top plot represents SCD values of sn1 chain and the bottom plot 
represents SCD values of sn2 chain of lipids. The experimental values 
are from the sn2 chain in both parts. Experimental deuterium order 
parameter is taken from [212]. All value is for 310 K(35 C). 
3.2 Conformational Stability and Flexibility 
The Root Mean Square Deviation (RMSD) of Cα atoms with respect to the initial 
conformation was calculated as a function of time to assess the conformational 
stability of the protein during the simulations (Figure 3.3). 
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Figure 3.3 :   RMSD of simulations. The Cα RMSD calculated for the 3 simulation 
systems. The other simulation results (AFMRF-noATP and ALLM) 
were not showed. 
According to Figure 3.3 APO simulation is equilibrated faster than other two 
simulations. The reason of this difference is that Pgp with substrate changed its 
conformation to adopt its substrate. To show this rearrangement in Figure 3.4 the 
RMSD values of LACAVA simulation presented for each sub domain. We can see 
easily from this graphic the reason of RMSD fluctuation of LACAVA Simulation is 
a result of fluctuation with transmembrane domains (TMD). If we extract these 
fluctuations from RMSD values the simulations were equilibrated around 4 ns. 
To identify the flexible regions of the protein, Root Mean Square Fluctuation 
(RMSF) of Cα atoms from its time averaged position was analyzed (Figure 3.5). 
Generally from APO to LACAVA, RMSF values are increased. Especially the NBD 
of LACAVA simulation is higher significantly than other simulations. Figure 3.6 
shows the b-factor values of LACAVA simulation and the increased fluctuation of 
NBD can be seen by changing its colour blue into red. 
Both RMSD and RMSF analysis give us opinion about convergence of simulation. 
According to these results and other quality control parameters like minimum 
distance between periodic images and energy terms (temperature, pressure, potential 
and kinetics energies) - these parameters are not showed in here - each simulation is 
quantifiable for further investigations. 
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Figure 3.4 :   RMSD of LACAVA simulation. This graphic represents RMDS values 
for each sub domains of Pgp. 
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Figure 3.5 :   RMSF of simulations. This graph shows RMSF values for each 
simulation. 
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Figure 3.6 :   B-factor representation of LACAVA simulation: This figure represents 
b-factors of Pgp according to LACAVA simulation. From blue to red, 
the b-factor (fluctuation) values increase. According to this 
representation ATP binding pocket and lactone atorvastatin pocket has 
high b-factors. In addition of this high-fluctuated region. Some intra-
domain regions has high b-factors like binding pockets. 
3.3 Principal Component Analysis (PCA) 
The prominent motions in the transporter during the course of simulation were 
analyzed with the help of PCA [207]. The principal motions for first eigenvectors of 
the three simulations are visualized using porcupine plot (see Figure 3.7). First 
eigenvector account for 40%, 37% and 76% of the motions in apo, AFMRF peptide 
and atorvastatin lactone bound simulations, respectively. 
We observed a concerted movement of TM helices within domains TMD1 and 
TMD2 during the simulations, suggesting a rigid body movement of these domains. 
The noticeable motion in the apo form simulation was a opening of the two 
transmembrane domains relative to one another, and is shown as a schematic 
diagram in Figure  3.7 APO. While in the case of atorvastation lactone bound form  
(see Figure 3.7 LACAVA), domains showed an closing motion type movement and 
TM4-5 and TM10-11 has a twisting motion in addition to closure. However, the 
molecular dynamics of AFMRF bound form of the transporter (see Figure 3.7 
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AFMRF) has a closing motion but its motion degree is lower than atorvastatin 
lactone bond form. 
 
 
Figure 3.7 :   PCA of Pgp simulations. The principal motions for first eigen vectors 
of the three simulations are represented in this figure. The direction of 
red arrows shows the direction of motion and the length of arrows 
shows the magnitude of motion. 
Proteins often accomplish their functions through collective atomic motions. To 
examine which residues undergo concerted motions, we analyzed the covariance 
matrix (see Figure 3.8) derived from the sets of conformations generated in the 10 ns 
simulations. This analysis highlighted regions of the protein that move together. The 
NBD1 (350-600) and NBD2 (residue 850-1200) has  intensive correlations with the 
opposite direction. Aside from anticipated correlations between NBD we can see that 
some transmembrane domains have correlations and moves with NBD domain. 
TM4-5 and TM10-11 were found to correlate with each other. 
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Figure 3.8 :   Covariance matrix of simulations. The matrix shows the covariance 
between atoms. Red means that two atoms move together, whereas 
blue means they move opposite to each other. The intensity of the red 
color is indicating the amplitude of the fluctuations. 
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3.4 Inter-helical Hydrogen Bonds 
Hydrogen bonds formed between TM helices are shown to play a critical role in 
stabilizing the tertiary structure of membrane proteins as well as in the 
conformational rearrangement required for specific functions [213]. We analyzed all 
possible inter-helical hydrogen bonds formed by Pgp during the time period of 
molecular dynamics simulation. Several inter and intra-domain hydrogen bonds were 
identified, and significant rearrangements of the hydrogen bonds were also observed 
in the three simulation systems. For LACAVA simulation, TM10-11, TM2-11 and 
TM9-7 interact with its counterpart through an increased hydrogen bonding (See 
Figure 3.9). TM9-7 interactions has special role its hydrogen bonding significantly 
increased when any substrate binded to Pgp. With LACAVA simulation TM1-2 
hydrogen bonding is higher than AFMRF and ALLM peptide bond form. 
To see big picture of hydrogen bonding profile it is possible to look only interdomain 
hydrogen bonding. Figure 3.10 shows that inter-transmembrane and inter-nucleotide 
binding domain interactions increased during simulation. Especially for TMDs and 
NBDs, inter-domain hydrogen bonding is increased during simulation and this 
increased hydrogen bonding stabilizes the closure of Pgp for LACAVA simulation. 
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Figure 3.9 :   LACAVA inter-helical hydrogen bonding. The hydrogen bonding 
number of LACAVA simulation for TM10-11, TM1-11 and TM9-7. 
The bonding profiles give opinion which transmembrane helices have 
more roles during transporting. 
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Figure 3.10 : Interdomain Hydrogen Bonding Profile. This plot show how the 
numbers of hydrogen bond between domains change during LACAVA 
simulation. According to this figure, the number of hydrogen bonding 
between TMD1-TMD2 and NBD1-NBD2 increased. However, the 
hydrogen bonding profile between TMD and NBD fluctuated and after 
for while this fluctuation is equilibrated. 
3.5 ATP Binding 
The catalytic cycle of Pgp involves the coupling of ATP binding and hydrolysis with 
substrate translocation across the cell membrane. Reactions taking place at the NBDs 
 
52 
during the catalytic cycle include ATP binding and formation of a nucleotide 
sandwich dimer, followed by ATP hydrolysis, Pi dissociation, and finally ADP 
dissociation. The simulation result of LACAVA simulation has asymmetric closure 
for ATP binding pocket. Although the simulation duration was short we could see 
the starting closure for one of the binding pocket of LACAVA system (see 
Figure 3.13). The other APO (see Figure 3.11) and AFMRF (see Figure 3.12) 
simulations have no remarkable closure for ATP binding pocket. 
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Figure 3.11 : Distance between Walker A and LSGGQ for APO simulation. This 
plot show how distance between Walker A and LSGGQ signature 
motif changed during simulation. According to this plot after a 
fluctuation, the distances for each pocket are equilibrated. Any closure 
motion for NBDs was not seen. 
The simulation results show that only for LACAVA simulation has a closure motion 
for one of its ATP binding pocket. And this closure motion is asymmetric closure as 
defined previous studies [120]. A few simulation studies which were done for 
Sav1866 MDR protein [214,215] concluded same result with this LACAVA 
simulation. As discussed previously in introduction section the asymmetric ATP 
hydrolyses is suggested [120] for MDR proteins. And the LACAVA result is 
matching to this mechanism. But the duration of simulation is not enough to be sure 
whether or not the asymmetric closure for LACAVA is final conformation of this 
simulation. Because this conformation can be results of random starting conditions 
and can leave this conformation with longer simulation. 
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Figure 3.12 : Distance between Walker A and LSGGQ for AFMRF simulation: This 
plot show how distance between Walker A and LSGGQ signature 
motif changed during simulation. According to this plot there, the 
fluctuation of distance value was not equilibrated and any closure for 
ATP binding pocket was not seen. 
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Figure 3.13 : Distance between Walker A and LSGGQ for LACAVA 
simulation. This plot show how distance between Walker A and 
LSGGQ signature motif changed during simulation. According to this 
plot, we can see that there is a closure in one of the ATP binding 
pockets. The other ATP binding pocket not closing one was fluctuated 
during simulation. 
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4.  CONCLUSION 
P-Glycoprotein is a drug transporter of the ABC superfamily that functions as an 
ATP-powered drug efflux pump. Rapid progress has been made in recent years in 
understanding the three-dimensional structure and ATP hydrolysis cycle of this 
protein, and many tools are now available for its study at the molecular level. 
Although the transporter can interact with hundreds of nonpolar, weakly amphipathic 
compounds with no apparent structural similarity, progress is being made in 
developing a pharmacophore model to describe its binding regions. The protein 
appears to interact with its multiple substrates via a large flexible drug-binding 
pocket, to which drugs gain access from the bilayer, leading to the suggestion that it 
is a “vacuum cleaner” for hydrophobic compounds that concentrate within the 
membrane. The drug transport mechanism of Pgp is poorly described and may 
involve “flipping” of substrates from the inner to the outer membrane leaflet. The 
primary physiological role of the protein appears to be the protection of sensitive 
organs and tissues from xenobiotic toxicity. Many drugs used in clinical therapy are 
P-glycoprotein substrates, and the transporter is now increasingly recognized to play 
a central role in the absorption and disposition of many drugs, including 
chemotherapeutic agents. Other compounds, known as modulators, that block the 
drug efflux function of Pgp are under development and may have clinical 
applications in the future.  
With release of crystal structure of Pgp, molecular dynamic simulation can create 
great opportunities to discover Pgp mechanism. If we resolve the mechanism of Pgp 
we can increasingly rationalize the drug development process of disease like cancer. 
Molecular dynamics simulation gives us to investigate atomistic level mechanism. 
This study investigated Pgp mechanism with some linear peptides and lactone 
atorvastatin. Because of low resolution of structure of Pgp there is some problem to 
investigate structure. Although this obstacle about structure we can say that Pgp 
interacted with lactone form of atorvastatin and has asymmetrical closure of 
nucleotide binding domains as we see with other MDR proteins like Sav1866.   
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In spite of atorvastatin interaction with Pgp, any meaningful interactions with linear 
peptides were not seen from simulation results.  These peptides were selected 
because both ALLM (N-acetyl-leu-leu-met-al) and AFMRF (N-acetyl-phe-met-phe-
arg-phe-al) are characterized as a substrates of Pgp and topology preparation was not 
required. There are some possible reasons for non-interactions between peptides and 
Pgp.  One of these reasons can be that single peptide was not enough to interact with 
Pgp.  Because we have known that Pgp has large polyspecific drug binding pocket 
and can transport more than one molecule per transport cycle.  
Ideas for further studies arising from the results of this work are manyfold. First, 
simulations of lactone atorvastatin should be continued to further understand the 
mechanism of Pgp and which residues are critic for transportation and to develop 
ways to better combine simulations with experiments. Also, work on acid form of 
atorvastatin should be investigated to understand which form of atorvastatin interacts 
with Pgp. In addition to atorvastatin, other statin molecules should be included in 
simulation to understand the drug metabolism of statins.  
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